Iberdomide Explained

Drug Name:Iberdomide
Cas Number:1323403-33-3
Pubchem:67335295
Unii:8V66F27X44
Drugbank:DB12101
Chemspiderid:52085251
Chembl:3989927
Kegg:D11134
Iuphar Ligand:9618
Iupac Name:(3S)-3-[7-[[4-(Morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
Smiles:C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5
Stdinchi:1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1
Stdinchikey:IXZOHGPZAQLIBH-NRFANRHFSA-N
C:25
H:27
N:3
O:5

Iberdomide is an experimental thalidomide analog[1] that works as an cereblon E3 ligase modulator; it has a higher binding affinity than lenalidomide or pomalidomide. It is developed by Bristol Myers Squibb for various cancers[2] [3] [4] [5] [6] [7] [8] and was also tested in people with lupus.[9]

Notes and References

  1. Gao . Shaobing . Wang . Shichao . Song . Yongping . Novel immunomodulatory drugs and neo-substrates . Biomarker Research . December 2020 . 8 . 1 . 2 . 10.1186/s40364-020-0182-y . 31938543 . 6953231 . free .
  2. Ye . Ying . Gaudy . Allison . Schafer . Peter . Thomas . Michael . Weiss . Daniel . Chen . Nianhang . Liu . Liangang . Xue . Yongjun . Carayannopoulos . Leon . Palmisano . Maria . First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator . Clinical Pharmacology in Drug Development . May 2021 . 10 . 5 . 471–485 . 10.1002/cpdd.869. 32969202 . 8246954 .
  3. Bjorklund . Chad C. . Kang . Jian . Amatangelo . Michael . Polonskaia . Ann . Katz . Mark . Chiu . Hsiling . Couto . Suzana . Wang . Maria . Ren . Yan . Ortiz . Maria . Towfic . Fadi . Flynt . J. Erin . Pierceall . William . Thakurta . Anjan . Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN . Leukemia . April 2020 . 34 . 4 . 1197–1201 . 10.1038/s41375-019-0620-8 . 31719682 . 7214241 . en . 1476-5551.
  4. van de Donk . Niels W.C.J. . Popat . Rakesh . Larsen . Jeremy . Minnema . Monique C. . Jagannath . Sundar . Oriol . Albert . Zonder . Jeffrey . Richardson . Paul G. . Rodriguez-Otero . Paula . Badros . Ashraf Z. . Stadtmauer . Edward . Bringhen . Sara . Campagnaro . Erica . Siegel . David S. . Gamberi . Barbara . Gironella Mesa . Mercedes . Sonneveld . Pieter . Nguyen . Tuong Vi . Di Micco . Antonia . Sorrell . April . Chen . Min . Amatangelo . Michael . Kueenburg . Elisabeth . Lonial . Sagar . First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) . Blood . 5 November 2020 . 136 . Supplement 1 . 16–17 . 10.1182/blood-2020-137743. 228828103 . free .
  5. Thieblemont . Catherine . Munoz . Javier . Tucci . Alessandra . Visco . Carlo . Cartron . Guillaume . Corradini . Paolo . Flinn . Ian W. . Gastinne . Thomas . Bouabdallah . Kamal Krimo . Arcaini . Luca . Nowakowski . Grzegorz S. . Roulin . Louise . Topp . Max . Jauhari . Shekeab . Vucinic . Vladan . Martin . Peter . Gkasiamis . Argyrios . Drew . James . Rao . Parth . Kaplan . Mark . Cheng . Yiming . Li . Ju . Morschhauser . Franck . Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study . Blood . 15 November 2022 . 140 . Supplement 1 . 569–572 . 10.1182/blood-2022-162559. 256795199 . free .
  6. Lonial . Sagar . Amatangelo . Michael . Popat . Rakesh . Minnema . Monique C. . Zonder . Jeffrey A. . Larsen . Jeremy . Oriol Rocafiguera . Albert . Campagnaro . Erica L. . Rodriguez Otero . Paula . Badros . Ashraf Z. . Siegel . David S. . Jagannath . Sundar . Bringhen . Sara . Gironella . Mercedes . Kaiser . Martin F. . Cook . Gordon . Gamberi . Barbara . Sonneveld . Pieter . Nguyen . Tuong Vi . Chen . Min S. . Homan . Trevor . Bjorklund . Chad C. . Wang . Maria . Pierceall . William E. . Bensmaine . Amine . Thakurta . Anjan . Peluso . Teresa . Van De Donk . Niels W. C. J. . Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220) . Blood . 13 November 2019 . 134 . Supplement_1 . 3119 . 10.1182/blood-2019-124298. 209233746 . free .
  7. Amatangelo . Michael . Bjorklund . Chad C. . Kang . Jian . Polonskaia . Ann . Viswanatha . Sridevi . Thakurta . Anjan . Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro . Blood . 29 November 2018 . 132 . Supplement 1 . 1935 . 10.1182/blood-2018-99-113383. 91382999 . free .
  8. Lonial . Sagar . Popat . Rakesh . Hulin . Cyrille . Jagannath . Sundar . Oriol . Albert . Richardson . Paul G . Facon . Thierry . Weisel . Katja . Larsen . Jeremy T . Minnema . Monique C . Abdallah . Al-Ola . Badros . Ashraf Z . Knop . Stefan . Stadtmauer . Edward A . Cheng . Yiming . Amatangelo . Michael . Chen . Min . Nguyen . Tuong Vi . Amin . Alpesh . Peluso . Teresa . van de Donk . Niels W C J . Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial . The Lancet Haematology . November 2022 . 9 . 11 . e822–e832 . 10.1016/S2352-3026(22)00290-3. 36209764 . 252779185 .
  9. Merrill . Joan T. . Werth . Victoria P. . Furie . Richard . van Vollenhoven . Ronald . Dörner . Thomas . Petronijevic . Milan . Velasco . Jorge . Majdan . Maria . Irazoque-Palazuelos . Fedra . Weiswasser . Michael . Korish . Shimon . Ye . Ying . Gaudy . Allison . Schafer . Peter H. . Liu . Zhaohui . Agafonova . Nataliya . Delev . Nikolay . Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus . New England Journal of Medicine . 17 March 2022 . 386 . 11 . 1034–1045 . 10.1056/NEJMoa2106535. 35294813 . 247499089 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Iberdomide".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.